Yes , what we are hearing , for FDA efficacy is the most important . and they will not look at some subgroup.
So 82% in leronlimab CD12 study , 82% in mortality benefit ABOVE any other drug in a dying , critical patients was not even looked at..
So why this subgroup pf patients , patient below 5 years old , patients at VERY low risk of dying , or developing severe sickness , had this vaccine approved for them ..after study showing VERY low efficacy